West Pharmaceutical Services (NYSE:WST) Releases Earnings Results, Beats Estimates By $0.45 EPS
by Jessica Moore · The Cerbat GemWest Pharmaceutical Services (NYSE:WST – Get Free Report) released its earnings results on Thursday. The medical instruments supplier reported $2.13 earnings per share for the quarter, beating analysts’ consensus estimates of $1.68 by $0.45, Zacks reports. West Pharmaceutical Services had a net margin of 16.06% and a return on equity of 17.90%. During the same quarter in the prior year, the company posted $1.45 earnings per share. The firm’s revenue was up 21.0% compared to the same quarter last year. West Pharmaceutical Services updated its FY 2026 guidance to 8.400-8.750 EPS and its Q2 2026 guidance to 2.050-2.120 EPS.
Here are the key takeaways from West Pharmaceutical Services’ conference call:
- West reported a strong Q1 with revenues of $845M (+21% reported, +15% organic) and adjusted EPS of $2.13, and raised full‑year guidance to 7%–9% organic revenue growth and $8.40–$8.75 adjusted EPS.
- HVP components remain the main growth engine—organic HVP components growth was ~23%, GLP‑1s represented ~10% of company sales, biologics were up 26%, and Annex I / HVP conversion is expected to add ~200 bps to revenue growth in 2026.
- Margins and capital returns improved: adjusted operating margin expanded to 21.4% ( +350 bps Y/Y), the board authorized a $1B share buyback and the company repurchased $298M of shares in Q1.
- Near‑term headwinds include a ~$40M CGM contract roll‑off in H2, and rising oil/commodity costs (management expects a net impact of low‑single‑digit millions after mitigation), which could pressure second‑half cadence and margins.
West Pharmaceutical Services Price Performance
NYSE WST traded up $35.36 on Thursday, hitting $309.77. The stock had a trading volume of 1,170,258 shares, compared to its average volume of 961,311. West Pharmaceutical Services has a 52-week low of $199.89 and a 52-week high of $322.34. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.34 and a current ratio of 3.02. The company has a market capitalization of $22.33 billion, a price-to-earnings ratio of 45.62, a price-to-earnings-growth ratio of 2.92 and a beta of 1.15. The firm has a 50-day moving average of $250.67 and a 200-day moving average of $261.77.
West Pharmaceutical Services Announces Dividend
The company also recently announced a quarterly dividend, which will be paid on Wednesday, May 6th. Shareholders of record on Wednesday, April 29th will be paid a $0.22 dividend. The ex-dividend date is Wednesday, April 29th. This represents a $0.88 annualized dividend and a yield of 0.3%. West Pharmaceutical Services’s dividend payout ratio is currently 12.96%.
Analyst Upgrades and Downgrades
A number of research analysts have recently weighed in on WST shares. Jefferies Financial Group reissued a “buy” rating and set a $295.00 target price on shares of West Pharmaceutical Services in a research report on Tuesday, February 10th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and set a $315.00 target price on shares of West Pharmaceutical Services in a research report on Friday, February 13th. Zacks Research cut shares of West Pharmaceutical Services from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, April 14th. Evercore dropped their price target on shares of West Pharmaceutical Services from $390.00 to $320.00 and set an “outperform” rating on the stock in a research note on Tuesday, February 3rd. Finally, Barclays upped their price target on shares of West Pharmaceutical Services from $265.00 to $275.00 and gave the company an “equal weight” rating in a research note on Tuesday, April 14th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $315.67.
Read Our Latest Report on West Pharmaceutical Services
Institutional Trading of West Pharmaceutical Services
Institutional investors and hedge funds have recently bought and sold shares of the company. DV Equities LLC purchased a new stake in West Pharmaceutical Services in the 4th quarter worth approximately $28,000. CYBER HORNET ETFs LLC purchased a new stake in West Pharmaceutical Services in the 2nd quarter worth approximately $25,000. Meeder Asset Management Inc. lifted its stake in West Pharmaceutical Services by 1,023.5% in the 4th quarter. Meeder Asset Management Inc. now owns 191 shares of the medical instruments supplier’s stock worth $53,000 after purchasing an additional 174 shares in the last quarter. MUFG Securities EMEA plc purchased a new stake in West Pharmaceutical Services in the 2nd quarter worth approximately $47,000. Finally, State of Wyoming purchased a new stake in West Pharmaceutical Services in the 2nd quarter worth approximately $49,000. 93.90% of the stock is currently owned by hedge funds and other institutional investors.
West Pharmaceutical Services announced that its board has initiated a stock buyback program on Tuesday, February 17th that permits the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization permits the medical instruments supplier to repurchase up to 5.6% of its stock through open market purchases. Stock repurchase programs are generally a sign that the company’s board of directors believes its stock is undervalued.
West Pharmaceutical Services News Summary
Here are the key news stories impacting West Pharmaceutical Services this week:
- Positive Sentiment: Q1 results materially beat expectations: GAAP EPS of $2.13 vs. consensus ~$1.68 and revenue growth of ~21% year‑over‑year, signaling solid top‑line momentum. Zacks: Q1 beat
- Positive Sentiment: Company raised FY2026 guidance to EPS $8.40–$8.75 (above Street) and revenue target to $3.3–$3.4B, and raised Q2 EPS and revenue ranges — signaling management’s confidence in sustained demand. PR Newswire: Press release
- Positive Sentiment: Management attributes strength to continued demand for proprietary packaging components (syringes, cartridges) and growth in high‑value segments (including GLP‑1 and other injectables), which supports higher margins and recurring revenue. Seeking Alpha: demand drivers
- Neutral Sentiment: Company provided additional disclosure (press release, slide deck and conference call) for investors to assess segment performance and margins; listen/see slides for detail on geographic and product mix. Slide deck / press materials
- Negative Sentiment: Valuation is elevated after the move — trailing P/E near mid‑40s — which could limit near‑term upside if growth moderates or the macro backdrop weakens. MarketBeat: valuation & metrics
West Pharmaceutical Services Company Profile
West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.
In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.